Floatz logo

Cyclophosphamide

Lung Non-Small Cell Squamous Carcinoma

PfizerSmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lung Non-Small Cell Squamous Carcinoma cohort.

Asset / SponsorPhaseRating
Epirubicin
Shanghai Henlius Biotech
Phase 3BBB
Rucaparib
SWOG Cancer Research Network
Phase 2CCC
vx-970
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →